|
000
| 02443nam 2200421zi 4500 |
|---|
| 001 | 9.934797 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20240410112705 |
|---|
| 006 | m o d f |
|---|
| 007 | cr mn||||||||| |
|---|
| 008 | 240301e20240308onc ob f000 0 eng d |
|---|
| 020 | |a9780660705675|q(report) |
|---|
| 020 | |a9780660705682|q(summary) |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aHP40-352/1-2024E-PDF |
|---|
| 086 | 1 |aHP40-352/2-2024E-PDF |
|---|
| 245 | 00|aUpdated guidance on the use of protein subunit COVID-19 vaccine (Novavax Nuvaxovid). |
|---|
| 264 | 1|aOttawa, ON : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |cMarch 8, 2024. |
|---|
| 264 | 4|c©2024 |
|---|
| 300 | |a1 online resource (12 pages, 3 unnumbered pages) + |e1 summary (4 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aCover title. |
|---|
| 500 | |aIssued also in French under title: Mise à jour des directives sur l'utilisation du vaccin à sous-unités protéiques contre la COVID-19 (Nuvaxovid de Novavax). |
|---|
| 500 | |aAt head of title: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). |
|---|
| 500 | |aPub.: 230829 (report). Pub.: 230831 (summary). |
|---|
| 504 | |aIncludes bibliographical references. |
|---|
| 650 | 0|aCOVID-19 vaccines|zCanada. |
|---|
| 710 | 2 |aPublic Health Agency of Canada, |eissuing body. |
|---|
| 710 | 1 |aCanada. |bNational Advisory Committee on Immunization, |eissuing body. |
|---|
| 775 | 08|tMise à jour des directives sur l'utilisation du vaccin à sous-unités protéiques contre la COVID-19 (Nuvaxovid de Novavax).|w(CaOODSP)9.934798 |
|---|
| 856 | 40|qPDF|s638 KB|uhttps://publications.gc.ca/collections/collection_2024/aspc-phac/HP40-352-1-2024-eng.pdf|zReport |
|---|
| 856 | 40|qPDF|s485 KB|uhttps://publications.gc.ca/collections/collection_2024/aspc-phac/HP40-352-2-2024-eng.pdf|zSummary |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-updated-guidance-use-protein-subunit-covid-19-vaccine-novavax-nuvaxovid.html|zReport |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-summary-updated-guidance-use-protein-subunit-covid-19-vaccine-novavax-nuvaxovid.html|zSummary |
|---|